Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RGLS 
Regulus Therapeutics Inc (RGLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RGLS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.57% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 115.93M USD | Price to earnings Ratio - | 1Y Target Price 10.83 |
Price to earnings Ratio - | 1Y Target Price 10.83 | ||
Volume (30-day avg) 1573227 | Beta 1.41 | 52 Weeks Range 0.83 - 2.90 | Updated Date 04/1/2025 |
52 Weeks Range 0.83 - 2.90 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.2225 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.42% | Return on Equity (TTM) -95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40427922 | Price to Sales(TTM) 7.43 |
Enterprise Value 40427922 | Price to Sales(TTM) 7.43 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 66243400 | Shares Floating 48557725 |
Shares Outstanding 66243400 | Shares Floating 48557725 | ||
Percent Insiders 2.18 | Percent Institutions 82.48 |
Analyst Ratings
Rating 4.5 | Target Price 10.33 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Regulus Therapeutics Inc
Company Overview
History and Background
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNA (miRNA) therapeutics. Founded in 2007, the company has focused on miRNA-based drug discovery and development. It has gone through several phases of clinical trials and corporate restructuring.
Core Business Areas
- miRNA Therapeutics Development: Regulus focuses on developing oligonucleotide therapeutics that target specific microRNAs to treat diseases. Their pipeline includes programs in kidney diseases and other therapeutic areas.
- Research and Discovery: The company conducts research to identify and validate miRNA targets relevant to disease and develop novel therapeutic candidates.
Leadership and Structure
The leadership team includes executives with experience in biotechnology, drug development, and finance. Organizational structure is typical for a small-cap biopharmaceutical company with departments for research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- RGLS4326: An oligonucleotide targeting miR-17 family for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Currently in clinical development. Competitors include Sanofi, Otsuka Pharmaceutical Co.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and potential for high returns. miRNA therapeutics is a relatively new field within this broader industry, facing both opportunities and challenges related to scientific validation and clinical development.
Positioning
Regulus Therapeutics is a specialized player in the miRNA therapeutics field, focusing on a specific technology platform. Competitive advantages include expertise in miRNA biology and intellectual property related to miRNA targets and therapeutic oligonucleotides.
Total Addressable Market (TAM)
The TAM for miRNA therapeutics is potentially large, driven by the involvement of miRNAs in numerous diseases. Exact TAM is difficult to estimate due to the early stage of the field. Regulus is positioned to capture a segment of the market by focusing on specific diseases and miRNA targets.
Upturn SWOT Analysis
Strengths
- Expertise in miRNA biology
- Proprietary technology platform
- Lead product candidate in clinical development
- Focus on specific disease targets
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Reliance on key personnel
- High risk associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new miRNA targets
- Positive clinical trial results leading to regulatory approval
- Advancements in oligonucleotide delivery technologies
Threats
- Clinical trial failures
- Competition from other therapeutic modalities
- Regulatory hurdles
- Patent disputes
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- SNY
- OTSKF
Competitive Landscape
Regulus Therapeutics is a smaller player compared to larger pharmaceutical companies. Its advantage lies in its focused expertise in miRNA therapeutics. Disadvantages include limited financial resources and dependence on clinical trial outcomes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of advancement in clinical development followed by financing rounds and strategic shifts.
Future Projections: Future growth is dependent on the success of RGLS4326 in clinical trials and the development of new miRNA-based therapeutics. Analyst estimates are not available without a live financial data feed.
Recent Initiatives: Recent initiatives include advancing RGLS4326 through clinical trials, exploring potential partnerships, and managing operating expenses.
Summary
Regulus Therapeutics is a small-cap biopharmaceutical company focused on miRNA therapeutics. While it has a specialized technology platform and a lead product candidate in clinical development, the company faces significant risks related to clinical trial outcomes, competition, and financial resources. Success hinges on the positive results from RGLS4326 and the ability to secure funding or partnerships for future development. Its specialization could attract larger companies looking to add miRNA capabilities.
Similar Companies
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is based on available information and may not reflect real-time values. An investment into RGLS involves a high degree of risk and could result in financial loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regulus Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-10-04 | CEO & Director Mr. Joseph P. Hagan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.regulusrx.com |
Full time employees 34 | Website https://www.regulusrx.com | ||
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.